Chronic migraine is a long-term neurological condition that can significantly affect daily life, work, and overall well-being. It is generally defined as experiencing headache symptoms on 15 or more days per month, with at least some of those headaches having migraine features. Managing this condition has historically been difficult, especially for patients who do not respond well to traditional medications.
A recent large-scale scientific review has brought renewed attention to newer treatment options that target migraine at its biological source. The findings suggest that a modern class of drugs known as CGRP-targeted therapies may offer better outcomes in both reducing migraine frequency and minimizing side effects when compared with older treatment approaches.
The study, published in the Annals of Internal Medicine, analyzed 43 clinical trials involving adults living with chronic migraine. Researchers focused on comparing different medication types, including both newer and older therapies, to understand which provided the most consistent relief.
One of the most important findings was that CGRP-targeted therapies demonstrated the strongest overall evidence for effectiveness. These medications were associated with an average reduction of about two migraine days per month. While that number may seem modest, for individuals experiencing frequent migraines, even small reductions can meaningfully improve quality of life.
These treatments were also generally well tolerated, meaning patients reported fewer and less severe side effects compared to older medications.
CGRP stands for calcitonin gene-related peptide, a protein found in the nervous system and brain. During migraine attacks, levels of CGRP increase, which contributes to inflammation, pain signaling, and the widening of blood vessels in the brain.
Newer medications are designed to block or reduce the activity of this protein. By interfering with this process, they can help prevent migraines from developing or reduce their severity when they do occur.
Examples of CGRP-targeted treatments include:
These treatments come in several forms, including injections, infusions, oral tablets, and nasal spray options, offering flexibility depending on patient needs and preferences.
The review also examined older, commonly prescribed migraine medications such as:
While these drugs are still widely used, the evidence supporting their effectiveness in chronic migraine prevention was found to be less consistent in comparison to newer therapies. In addition, they were more likely to be associated with side effects that lead some patients to stop treatment early.
Another treatment option analyzed was botulinum toxin injections, commonly known as Botox. This therapy showed some benefit in reducing migraine frequency, but the evidence was less certain overall. Researchers also noted higher variability in patient response and concerns about side effects contributing to treatment discontinuation.
One of the key reasons CGRP-targeted therapies are becoming more widely discussed in medical settings is their balance of effectiveness and tolerability. Many patients with chronic migraine struggle not only with pain but also with the side effects of older medications, which can include fatigue, cognitive difficulties, or mood changes.
The newer treatments appear to offer a more targeted approach, focusing directly on the biological pathway involved in migraine attacks rather than broadly affecting brain activity. This precision may explain why patients report fewer adverse effects overall.
Despite promising results, researchers caution that more long-term studies are needed. Many of the current trials focus on short to medium-term outcomes, meaning there is still limited data on long-term safety, effectiveness, and adherence over several years.
The research team, led by Malahat Khalili from the Michael G. DeGroote Institute for Pain Research and Care at McMaster University in Canada, emphasized the importance of continued independent studies. These will help ensure that the benefits observed in clinical trials translate into real-world settings over time.
Even though CGRP-targeted therapies show strong results overall, they are not necessarily the right choice for every patient. Treatment decisions for chronic migraine should always consider individual factors such as:
Healthcare providers typically take a personalized approach when recommending migraine treatments, often trying multiple options before finding the most effective regimen.
The development of CGRP-targeted therapies represents a significant shift in migraine care. Instead of relying primarily on medications that were originally designed for other conditions, researchers are now focusing directly on migraine-specific biological mechanisms.
As more data becomes available, it is likely that treatment guidelines will continue to evolve. Future research may also explore combination therapies or new delivery methods that further improve outcomes for patients living with chronic migraine.
The latest evidence suggests that newer CGRP-targeted medications may offer meaningful improvements for people living with chronic migraine. These treatments have shown the ability to reduce monthly headache days while producing fewer side effects compared to many older medications.
However, experts emphasize that treatment should always be individualized. Patients are encouraged to work closely with healthcare professionals to determine the most appropriate option based on their unique needs.
While more long-term research is still needed, the current findings represent an encouraging step forward in the ongoing effort to improve migraine care.
Source: Khalili, M., Haghdoost, F., Liaghatdar, A., Torabiardakani, K., Mahdian, F., Levit, T., Moradi, S., & Sadeghirad, B. (2026, May 5). Effectiveness and tolerability of pharmacologic prophylaxis for chronic migraine: A systematic review of randomized controlled trials. Annals of Internal Medicine.
This article is for informational and educational purposes only and is not intended to provide medical advice, diagnosis, or treatment. Medical information and statistical findings do not apply equally to all individuals. Always consult a qualified healthcare professional before starting, stopping, or changing any medical treatment.
Most Accurate Healthcare AI designed for everything from admin workflows to clinical decision support.